Health Economics›Classical Hodgkin lymphoma›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Classical Hodgkin lymphoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ABVD Variant #01	—	R 2 916	28d	—	—	—	—	4
ABDIC Variant #01 Partial	—	R 2 908	28d	—	—	—	—	—
CEP Variant #01	—	R 2 001	28d	—	—	—	—	—
BVDS Variant #01 Partial	—	R 877	30d	—	—	—	—	—
B-CAVe Variant #01 Partial	—	R 820	42d	—	—	—	—	—
CVB Variant #01 Partial	—	R 589	28d	—	—	—	—	—
SCAB Variant #01 Partial	—	R 431	30d	—	—	—	—	—
CVPP Variant #01 Partial	—	R 430	28d	—	—	—	—	—
BVCPP Variant #01 Partial	—	R 429	28d	—	—	—	—	—

9 of 9 regimens shown